Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association.

Abstract

The Piedmont Oncology Association conducted a Phase II trial of fluoxymesterone (Halotestin) in 28 patients who failed to respond to prior hormonal therapy with tamoxifen and a progestational agent. Of nine patients who had responded to prior endocrine therapy, one had a partial response (PR) as defined by strict criteria and remains on study at 17 + months for an 11% response rate [95% confidence interval (CI), complete response (CR) + PR, 0-48%]. None of 19 previously unresponsive patients achieved remission (95% CI, CR + PR, 0-18%). Eleven patients' performance status deteriorated during therapy. Five of them had not received prior chemotherapy, and their response to subsequent chemotherapy may have been adversely affected. Third-line hormonal therapy with fluoxymesterone can be recommended only as a temporizing measure in patients with indolent disease who have responded to prior hormonal therapy.

• Authors: D J Schifeling, D V Jackson, P J Zekan, H B Muss
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 15 Issue 3 Pg. 233-5 (Jun 1992) ISSN: 0277-3732 [Print] United States
• PMID: 1590276 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Fluoxymesterone

Topics

• Adult
• Aged
• Aged, 80 and over
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Fluoxymesterone (therapeutic use)
• Humans
• Middle Aged